Zydus Cadila to seek approval for two-dose regimen of its approved three-dose Covid-19 vaccine in India | India News
Indian Medicines Regulator for Emergency Use in India on Aug 20.
Trials for the two-dose regimen are ongoing. 2 mg of the vaccine has been prescribed in each dose from the actuality
three-dose vaccine, that is, a total of 6 mg. The company is now evaluating a 2-dose regimen with 3mg in each dose.
The vaccine is said to be groundbreaking, as it is the first time that a technologically advanced vaccine has been successfully developed on the plasmid DNA platform for human use.
A plasmid DNA vaccine uses DNA molecules that do not replicate. According to Zydus Cadila, the vaccine that when administered produces the peak protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arm of the human immune system, which plays a vital role in protecting against diseases such as as well as viral clearance.
The platform due to its fast plug-and-play technology can be easily adapted to deal with mutations in the virus, such as those that are already occurring. The company plans to manufacture 10 to 12 crore doses of ZyCoV-D annually.
The vaccine is stored at 2-8 degrees Celsius. Unlike the Pfizer and Moderna vaccines that must be stored at a very cold temperature, ZyCoV-D can be stored at 2 to 8 degrees. This vaccine is also effective against the Delta variant of Covid-19.
ZyCoV-D does not require a needle and is administered intradermally, which is done with PharmaJet, a needleless applicator that guarantees painless vaccination. This will help give the vaccine to children. The vaccine is likely to be available in early October, sources told ANI on Saturday.
Recently, in an exclusive interview with ANI, Dr. Sharvil Patel, Managing Director of Zydus Group He said that the supply of the vaccine will begin from October.
“The vaccine supply will start in mid-September and, starting in October, the supply will increase to one crore of doses per month,” Patel had said.
On the expected vaccine supply through December, Patel said the company expects to increase doses by 1 crore per month starting in October and will supply 4-5 crore doses per month until January 2022.
“We can increase the production of a vaccine up to Rs 1 million a month starting in October at the new production plant, and it is expected to deliver 4-5 million doses until January 2022,” he said.
According to the Ministry of Health and Family Welfare (MoHFW), with the administration of 72,86,883 doses of vaccine in the last 24 hours, the country’s COVID-19 vaccination coverage exceeded the accumulated figure of 73.82Cr (73.82, 07,378) as per interim reports until 7 am on Sunday. This has been achieved through 75,25,766 sessions, the ministry said.
Currently, the Covishield, Covaxin, and Sputnik V vaccines are being administered to the eligible population over 18 years of age.